Clinical Trials
2 trialsNCT03126630 2026-04-01
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT02839681 2019-05-21
Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated